Thomas Hartman Foundation for Parkinson’s Research, Inc.
Thomas Hartman Foundation for Parkinson’s Research, Inc.
Thomas Hartman Foundation for Parkinson’s Research, Inc. Scientific Research Advancements
Thomas Hartman Foundation for Parkinson’s Research, Inc.
Thomas Hartman Foundation, The Hartman Foundation, Hartman Foundation, Thomas Hartman, cure for Parkinson's disease, Parkinson, Parkinson's disease, Father Tom, Father Tom Hartman, Father Thomas Hartman, cure Parkinson's disease, Parkinson's Research, The God Squad
DonateAboutScientific Research AdvancementsNews & EventsCure for SureSponsor UsAsk the DoctorPrayer ChainResourcesContactHome

Scientists Hail Parkinson’s Brain Cells ‘Breakthrough’

Very encouraging and important research step to develop new  treatments to halt or reverse Parkinson’s disease.

 

Scientists are able to utilize skin cells from a patient with Parkinson’s disease to generate brain nerve cells that are affected by the disease to be able to see in great detail how Parkinson’s develops.  This step will enable scientists to study outside the brain the affected brain cells and how these cells live, how they die and why they are different.

 

This important breakthrough will also make it easier and faster to test new drugs and therapies to slow or halt progress of the disease. The goal is to find drugs that prevent the death of these key brain cells that are ravished by Parkinson’s disease. 

 

Dr. Andrew Feigin, Center for Neurosciences at The Feinstein Institute for Medical Research and also serves as a Director of the Board for the Thomas Hartman Foundation for Parkinson’s Research, Inc. states:  This is an important step because it may allow for more rapid screening of potential new treatments, especially “Neuroprotective” Therapies (keeping key brain cells that produce dopamine alive) to slow the progression of disease.  That is, novel treatments could be tested in the laboratory on actual Parkinson’s affected brain cells, before moving the testing to human trials.

 

 

Major Parkinson’s Breakthrough: Message of Hope

 

Very promising results on a novel, cutting-edge Gene Therapy on Parkinson’s disease; Patients experience dramatic improvement in the tremors, rigidity and other motor skill problems that are hallmarks of the illness.

 

Dr. Michael Kaplitt, Weill Cornell Medical Center, Department of Neurosurgery and Dr. Andrew Feigin, Center for Neurosciences at The Feinstein Institute both are Thomas Hartman Foundation for Parkinson’s Research Grant Recipients and Scientific Advisors for the Foundation.  Dr. Kaplitt’s Gene Therapy with Dr. Feigin as Principal Investigator and Senior Author showed exciting replicated, confirmed results in this follow-up  Phase 2 Clinical Trial which uses a harmless, inactive virus to deliver the GAD gene into the brain region of Parkinson’s patients which involves motor function.  In patients with Parkinson’s disease, their brains get overactive after losing the normal supply of a chemical called GABA. This new treatment, gene therapy, works by inserting billons of copies of a gene into the patients’ brains that helps them produce more GABA. Dr. Feigin was responsible for the medical monitoring of these patients via Brain Imaging at The Feinstein Institute.  This novel treatment is less invasive than Deep Brain Stimulation Therapy and can benefit many patients suffering from other Neurological Diseases.

 

Thomas Hartman Foundation Collaborative Scientific Research Program to Cure Parkinson's Disease: Click here (PDF)

Scientific Research Symposium

 

The Hartman Scientific Symposium was held at the Feinstein Institute in Manhasset  to celebrate some of the recent Hartman Foundation grant recipients, including David Eidelberg, MD, head of the Feinstein's Susan and Leonard Feinstein Center for Neurosciences and a leading Parkinson's researcher.  Dr. Eidelberg is also Chief Scientific Advisor to the Thomas Hartman Foundation.  The foundation awards grants annually to Parkinson's researchers in an effort to identify new insights into disease mechanisms and treatments.

On September 29th, Dr. David Eidelberg of The Feinstein Institute was endowed by the National Institute of Neurological Disorders and Stroke as one of 11 Morris K. Udall Centers of Excellence in Parkinson's Disease Research.

At the symposium on October 7th, four world-renowned scientists who have received Hartman Foundation funding discussed some of the latest Parkinson's research findings. "This meeting brings together the scientific leaders in the Parkinson's field," Dr. Eidelberg said.  "Many outstanding Parkinson's scientists have been recipients of support from the Hartman Foundation.  The Hartman Foundation will seek to continue and grow its enthusiastic support of cutting edge research in the field."

 

PARKINSON'S RESEARCH ADVANCES IN THE LAST 10 YEARS

DISCOVERY OF GENES FOR FAMILIAL PARKINSON'S DISEASEOver the past decade, several gene defects causing rare familial forms of Parkinson's have emerged.  Their resemblance to the common nongenetic form of Parkinson's lead many researchers to believe that investigating these rare cases will help acquire a better understanding as to how and why brain cells are dying in Parkinson's patients.

iPS TECHNOLOGY:  Induced Pluripotent Stem Cells from skin, blood or endometrial lining are reprogrammed to grow dopaminergic neurons lost in Parkinson's Disease.  These stem cells will be utilized to determine therapeutic and potential usefulness to search for mechanisms of degeneration and for drug testing.

NEUROINFLAMMATION IN PARKINSON'S DISEASEToxicity and Oxidative Stress lead to cell death.  Intense clinical basic researchers have shown that such inflammatory events may well contribute to the onset of Parkinson's and/or exacerbates its progression.

MITOCHONDRIAL BIOLOGY:  Critical findings have lead to the exciting new hypothesis that in Parkinson's it might exist that a progressive accumulation of defective mitochondria in brain cells, which, in turn, produce disastrous consequences including death of brain cells.

PARKINSON'S DISEASE CLASSIFIED IN STAGES:  Recognition that the Parkinson's Disease process moves through the brain slowly-work of Heiko Braak-6 stages of Parkinson's Disease.

RECOGNITION THAT NON-MOTOR MANIFESTATIONS OF PARKINSON'S ARE COMMON:  These non-motor manifestations occur much earlier than motor manifestations of Parkinson's.  Early screening and detection will enable resultant therapies to stop the progression of the disease.

DEEP BRAIN STIMULATION:  Recognition that Deep Brain Stimulation surgery is a reliable way to extend useful motor function in the later stages of Parkinson's when medications lose their effectiveness and side effects are worse than the disease itself.

FUNCTIONAL IMAGING AND PARKINSON'S DISEASE:  Recognition that it is possible to identify Parkinson's Disease from other Parkinsonian conditions for proper diagnosis and treatment.  Imaging also shows if medications are having a positive or a negative effect.

DEVELOPMENT OF NEW MOUSE MODELS:  Mouse models that give insight in LRRK2 genetic mutations, which is the potential cause of Parkinson's, to enable new treatments to be brought to the bedside.

Father Tom Hartman

 

To get our FREE THF Parkinson's Disease Newsletter
and up-to-date Research & Foundation News,
please enter your email address below.
Email:

Home About News & Events Cure for Sure Prayer Chain Resources Donate Contact

Privacy PolicyTerms of Use

Copyright © 2007 Thomas Hartman Foundation For Parkinson’s Research, Inc.